

CRS Report for Congress

Received through the CRS Web

Prescription Drug Coverage Under Medicaid

Updated February 21, 2006

Jean Hearne
Specialist in Social Legislation
Domestic Social Policy Division

Prescription Drug Coverage Under Medicaid

Summary

Medicaid is a joint federal-state entitlement program that pays for services on behalf of certain groups of low-income persons. One of its most important benefits is prescription drug coverage. Beginning in January 2006, many of Medicaid's elderly and disabled beneficiaries began receiving their drug coverage under Medicare. Nonetheless, Medicaid drug coverage remains an important source of drugs for many low-income and disabled Medicaid beneficiaries and for Medicaid financing, an important source of funding in the nation's pharmaceutical markets.

Outpatient prescription drug coverage under Medicaid is an optional benefit. If states choose to cover prescription drugs, they must be provided to Medicaid enrollees who are categorically needy, that is, to individuals who qualify for Medicaid on the basis of being in certain groups. In addition, states have the option of choosing to provide prescription drug coverage to medically needy individuals, persons who are not poor by cash welfare standards, but who require help with medical expenses. Thirty-three states and the District of Columbia provide prescription drug coverage to all Medicaid beneficiaries.

Prescription drug benefits under Medicaid are very broad. States can create formularies, or lists of preferred benefits, but certain federal rules keep actual coverage very comprehensive. Even in Medicaid managed care organizations, which are not subject to those rules, current practice combined with a directive from the Center for Medicare and Medicaid Services (CMS) ensures that drugs made available to fee-for-service enrollees must also be available to managed care enrollees. There are only 10 categories of prescription drugs that states are allowed to exclude from coverage and one category for which federal Medicaid funds cannot be used.

Based on state financial reports for 2004, payments for Medicaid outpatient prescription drugs, net of federal rebates, were \$30.4 billion, accounting for about 11% of payments for all Medicaid services. Since 1990, pharmaceutical manufacturers whose drugs are covered by state Medicaid programs are required to rebate a portion of states' payments for their products. States reported collecting a total of \$8.8 billion in federal rebates on prescription drugs in 2004. On average, in 2003, the last year for which prescription drug spending by enrollee are available, per-person spending for Medicaid drugs was almost \$1,120.¹

Under the new Medicare Part D drug benefit rules, state Medicaid programs will continue to contribute to the cost of drugs offered to the dually eligible population under Medicare based on a specified formula. In addition, Medicaid administrations will be required to conduct eligibility determinations for individuals qualifying for low-income assistance for the new Medicare program.

The Deficit Reduction Act of 2005 made a number of changes to the program's rules primarily relating to the financing of drugs and the cost sharing amounts that states are able to require Medicaid beneficiaries to pay for these drugs.

¹ CRS tabulations of CMS MSIS data for 2003.

Contents

Introduction	1
Prescription Drug Benefits	2
Fee-for-Service Coverage	4
Managed Care Coverage	5
Over-the-counter (OTC) Medications	5
Prescription Drugs — Pricing Policies and Rebates	6
Medicaid Drug Payments and Federal Upper Limits	6
States’ Payment Formulas	7
Dispensing Fees	10
Medicaid Drug Rebates	10
Single Source and “Innovator” Multiple Source Drugs	11
“Non-Innovator” Multiple Source Drugs	12
Drug Pricing and Rebate Issues	14
Average Wholesale Prices	14
Circumventing the Best Price or Rebate Policies	15
Supplemental Rebates	16
Controlling Drug Cost and Use	16
Prior Authorization	16
Prescribing/Dispensing Limitations	17
Drug Use Review	19
Cost Sharing Requirements for Medicaid Prescription Drugs	20
Other Cost Containment Strategies	22
Bulk Purchasing Programs	22
Importing Lower-Priced Drugs from Canada	23
Medicaid Spending for Outpatient Prescription Drugs	24
Medicaid Drug Spending by State	24
Spending by Eligibility Group	27
Number and Cost of Prescriptions Filled	28
Spending on Top Five Therapeutic Categories	29
Current Issues	29
Impact of MMA 2003	29
Pharmacy Plus	30
Glossary	31

List of Tables

Table 1. Medicaid Coverage of Outpatient Prescription Drugs, 2005	3
Table 2. States’ Payment Formulas as of March 2005	8
Table 3. Medicaid Rebate Formulas	13
Table 4. Medicaid Total Drug Spending and Rebates by State, 2004	13
Table 5. Medicaid Drug Prescription or Dispensing Limits, 2004	18
Table 6. Cost Sharing Requirements for Medicaid Pharmaceuticals as of March 2005	20

Table 7. Total Medicaid Spending and Medicaid Prescription Drug Spending and Percentage Change in Spending for Selected Years	24
Table 8. Total Medicaid Spending and Outpatient Drug Spending, 2004	26
Table 9. Average Medicaid Prescription Drug Spending Among Medicaid Prescription Drug Users by Basis of Eligibility, FY2003	28

Prescription Drug Coverage Under Medicaid

Introduction

Medicaid is a joint federal-state entitlement program that pays for medical services on behalf of certain groups of low-income persons. It is the third largest social program in the federal budget, exceeded only by Social Security and Medicare and is typically the second largest spending item for states. The federal share of Medicaid costs in FY2004 for benefits and administration is estimated to have been \$175 billion²; states are estimated to have spent an additional \$121 billion, for a total program cost of \$296 billion.

Medicaid programs are administered and designed by the states under broad federal guidelines. States must provide Medicaid to certain population groups and have the option of covering others. Similarly, a state must cover certain basic services and may cover additional services if it chooses. States set their own payment rates for services, with some limitations. There is, thus, considerable variation in Medicaid programs with some relatively limited and others very generous in terms of eligible populations, covered benefits and payments for services.

Medicaid is a means-tested program. Enrollees' income and other resources³ must be within program financial standards. These standards vary among states, and among different population groups within a state. With some exceptions, Medicaid is available only to persons with very low incomes — most Medicaid enrollees have income that is below the poverty level.

With a number of exceptions, Medicaid is available only to children, adult members of families with children, pregnant women, and to persons who are aged, blind, or disabled. Persons not falling into those categories — such as single adults and childless couples — generally cannot qualify no matter how low their income is.⁴ The various eligibility groups have traditionally been divided into two basic classes, the “categorically needy” and the “medically needy.” The two terms once distinguished between welfare-related (categorically needy) beneficiaries and those qualifying only under special Medicaid rules which allow states to cover persons whose income is too high to qualify for cash welfare support but who nevertheless need help with medical bills (medically needy). However, non-welfare groups have

² Preliminary FY2004 CMS Form 64 Financial Reports.

³ “Resources” include bank accounts and similar liquid assets, as well as real estate, automobiles, and other personal property whose value exceeds specified limits and usually exclude an individual’s primary residence.

⁴ Several states use special waivers of Medicaid’s eligibility rules to extend coverage to other groups of individuals not traditionally eligible.

been added to the “categorically needy” list over the years. As a result, the terms are no longer especially helpful in sorting out the various populations for whom mandatory or optional Medicaid coverage has been made available. However, the distinction remains important when considering certain benefits. Some benefits are considered mandatory for categorically needy individuals; that is, states must cover those benefits for the categorically needy but they are optional for medically needy individuals. Other benefits, including prescription drugs, are optional for both groups of beneficiaries. Some states provide those optional benefits only to categorically needy individuals, some states provide those benefits to both groups, and some provide those benefits to certain subcategories of medically needy as well as categorically needy.

Several recent laws have had and will continue to have a major impact on Medicaid prescription drug benefits. While specific provisions will be discussed in detail below, a summary of those major changes that affect prescription drugs for Medicaid beneficiaries are as follows.

The Medicare Prescription Drug, Improvements, and Modernization Act of 2003 (MMA, P.L. 108-173)

- established the Part D Medicare benefit. Effective January 1, 2006, all beneficiaries who are eligible for both Medicaid benefits and Medicare benefits will receive their drug coverage under the new Medicare Part D; and
- established a formula to continue the states’ contribution for the cost of prescription drugs provided to dually eligible beneficiaries whose drug coverage moved from Medicaid to Medicare upon implementation of Part D.

The Deficit Reduction Act of 2005 (DRA 2005, P.L. 109-171)

- changed the federal upper limit on drug costs under the Medicaid program;
- required that manufacturer-reported average manufacturer prices be publically available;
- included provisions intended to improve states’ ability to collect drug rebates for physician-administered and authorized generic drugs; and
- liberalized states’ ability to establish co-payments on prescription drugs for Medicaid beneficiaries.

Prescription Drug Benefits

Coverage of outpatient prescription drugs is optional for state Medicaid programs. States choose whether or not to include coverage of outpatient drugs in their Medicaid benefit package. In 2005, all states covered outpatient prescription drugs for at least some Medicaid beneficiaries; well more than half of the states reported covering outpatient drugs for all Medicaid beneficiaries. The remaining states covered drugs for at least categorically needy individuals (**Table 1**) and sometimes for other specified groups in addition to the categorically needy.

Prescription drug coverage is one of the few optional Medicaid services provided by all states. This is in part due to the belief that coverage of prescription drug benefits is a “good deal” — that the provision of this benefit can help to keep enrollees healthier and potentially prevent more serious and/or costly medical interventions.

Table 1. Medicaid Coverage of Outpatient Prescription Drugs, 2005

State	Categorically needy	Medically needy*
Alabama	X	
Alaska	X	
Arizona	X	X
Arkansas	X	X
California	X	X
Colorado	X	
Connecticut	X	X
Delaware	X	
District of Columbia	X	X
Florida	X	X
Georgia	X	X
Hawaii	X	X
Idaho	X	
Illinois	X	X
Indiana	X	
Iowa	X	X
Kansas	X	X
Kentucky	X	X
Louisiana	X	X
Maine	X	X
Maryland	X	X
Massachusetts	X	X
Michigan	X	X
Minnesota	X	X
Mississippi	X	
Missouri	X	
Montana	X	X
Nebraska	X	X
Nevada	X	
New Hampshire	X	X
New Jersey	X	X
New Mexico	X	
New York	X	X
North Carolina	X	X
North Dakota	X	X
Ohio	X	
Oklahoma	X	
Oregon	X	
Pennsylvania	X	
Rhode Island	X	X
South Carolina	X	

State	Categorically needy	Medically needy*
South Dakota	X	
Tennessee	X	X
Texas	X	For children and adults in families
Utah	X	X
Vermont	X	X
Virginia	X	X
Washington	X	X
West Virginia	X	X
Wisconsin	X	X
Wyoming	X	

Source: *Medicaid At-a-Glance, 2005; A Medicaid Information Source, Centers for Medicare and Medicaid Services*, Department of Health and Human Services, Publication No. CMS-11024-05.

Note: Arizona and Tennessee provide pharmaceutical coverage to all beneficiaries through programs operated under Section 1115 demonstration waivers. These programs do not recognize the federal distinction between categorically and medically needy.

* This column indicates drug coverage for only those states that include coverage of medically needy individuals under their state Medicaid plans.

Fee-for-Service Coverage. For Medicaid beneficiaries who are not enrolled in Medicaid managed care plans, federal statute allows states to establish formularies. “Formularies” are lists of preferred pharmaceuticals. When health care insurers or providers cover only those drugs on the list and deny payment for others, the list is referred to as a “closed formulary.” Medicaid formularies are seldom as restrictive as the closed formularies found in the private market for insurance because of two statutory requirements. The first requirement is that states must cover any non-formulary drug (with the exception of drugs in 10 specific categories — see below) that is specifically requested and approved through a prior authorization process.⁵ The second requires states to cover all drugs offered by manufacturers entering into rebate agreements with the Secretary of Health and Human Services (HHS).

While ensuring that Medicaid formularies are not too restrictive, federal statute does (Section 1927(d) of Medicaid law), on the other hand, clearly allow states to exclude the following categories of drug products from Medicaid coverage: drugs used (a) to treat anorexia, weight loss or weight gain; (b) to promote fertility; (c) for cosmetic purposes or hair growth; (d) for the relief of coughs and colds; (e) for smoking cessation; and (f) prescription vitamins and mineral products (except prenatal vitamins and fluoride preparations; (g) non-prescription drugs; (h) barbiturates; (i) benzodiazepines⁶; and (j) drugs requiring tests or monitoring that can only be provided by the drug manufacturer. Formularies may also exclude a drug for which there is no significant therapeutic advantage over other drugs that are included

⁵ Prior authorization is a process whereby a patient’s provider requests approval for coverage from the Medicaid agency or its contractor of a specific drug before dispensing that drug.

⁶ Barbiturates and benzodiazepines are drugs generally used as sedatives and tranquilizers.

in the formularies as long as there is a written explanation of the reason for its exclusion and the explanation is available to the public. Finally, as of January 1, 2006, federal law prohibits federal Medicaid funds from being used to pay for drugs for the treatment of sexual or erectile dysfunction.

Managed Care Coverage. For Medicaid beneficiaries who are enrolled in managed care plans, plans to which states pay a fixed monthly payment in exchange for the provision all or some subset of covered services, Medicaid statute includes a broad exception to the drug coverage rules described above.⁷ The law allows the enrolling managed care organization to develop and administer its own formulary. In practice, however, when prescription drugs are covered under the managed care arrangement, states enforce limitations on the formularies of managed care entities similar to those imposed on states by the federal government. This policy was initiated in correspondence from the Secretary of Health and Human Services (HHS) to State Medicaid Directors⁸. This letter notified states that drugs covered under the state plan must also be made available in Medicaid managed care formularies for Medicaid managed care enrollees. States generally establish contract clauses in their agreements with Medicaid health maintenance organizations (HMOs) and other managed care organizations (MCOs) that allow such entities to establish formularies but also require them to meet all of the fee-for-service coverage rules.

Over-the-counter (OTC) Medications. Many state Medicaid programs also cover OTC medications — or those medications that can be purchased without a prescription. A survey conducted by the National Pharmaceutical Council (NPC) questions states about Medicaid coverage of eight categories of non-prescription drugs: allergy, asthma, and sinus medications; analgesics; cough and cold medicines; smoking deterrents; digestive products; H2 antagonists (drugs used to treat ulcers and other stomach conditions); feminine products; and topical products. In 2004, all but one state reported covering some OTC drugs, in most cases limited coverage or coverage with restrictions. Nineteen states reported covering at least some OTC drugs in seven categories: allergy, asthma, and sinus; analgesics; cough and cold; smoking deterrents; digestive products; H2Antagonists; and topical products.⁹

In general, Medicaid pharmaceutical benefits are very broad, encompassing most prescription drugs and many non-prescription drugs. Medicaid beneficiaries receiving care in the fee-for-service sector are assured of broad pharmaceutical coverage due to statutory requirements that prohibit states with closed formularies from denying drugs requested and approved in the prior authorization process and those offered by manufacturers that have rebate agreements in effect. The benefits provided to Medicaid managed care enrollees tend to be similarly broad because of administrative policies.

⁷ Section 1927(j) of the Social Security Act.

⁸ Coverage of Protease Inhibitors — June 19, 1996.

⁹ Pharmaceutical Benefits Under State Medical Assistance Programs 2004, National Pharmaceutical Council at [<http://www.npcnow.org/resources/PharmBenefitsMedicaid.asp>].

State Medicaid programs will be undergoing major changes in their drug coverage policies over the next few years in response to the recent passage of MMA 2003. The law provides for a Medicare drug benefit for Medicaid beneficiaries who also qualify for Medicare. While specific information about the drugs that will be covered under Medicare is not available at this time, it is likely that Medicaid prescription drug coverage for dually eligible individuals will be considerably reduced since Medicaid programs are specifically prohibited from continuing to cover drug offered under the Medicare plans. State Medicaid programs will continue to be required to pay for drugs offered to the dually eligible population under Medicare, however, based on a formula specified in MMA 2003. The formula requires states to contribute an amount equal to 90% (declining to 75% over several years) of the per capita cost of states' drug spending under Medicaid in 2003 multiplied by the number of dual eligibles enrolling in the new Medicare benefit. In addition, Medicaid administrations will be required to conduct eligibility determinations for individuals qualifying for low-income assistance for the new program.

Prescription Drugs — Pricing Policies and Rebates

Medicaid Drug Payments and Federal Upper Limits

Medicaid reimbursement for outpatient prescription drugs has two components: an amount to cover the cost of the ingredients (the acquisition cost) and an amount to cover the pharmacist's professional services in filling and dispensing the prescription (the dispensing fee). Medicaid law requires the Secretary to establish upper limits on federal payments for acquisition costs that are designed to encourage the substitution of lower-cost generic equivalents for more costly brand-name drugs. Those federal upper limits (FULs) apply separately to multiple source drugs¹⁰ — those that have at least three therapeutically equivalent drug versions — and to all other drugs. The limits do not apply to individual claims for prescription drugs. Rather, the limits are applied in the aggregate to each state's spending for a particular drug. The DRA 2005, signed by the President on February 8, 2006, made several significant changes to the FUL policy for multiple source drugs. Those changes will become effective on January 1, 2007. The following paragraphs describe the existing FUL policy in effect until the effective date of DRA 2005, and those FUL policies that will go into effect after that date under DRA 2005.

The FULs for multiple source drugs are calculated by the Centers for Medicare and Medicaid Services (CMS) and are periodically published in the state Medicaid Manual.¹¹ These upper limits apply, in the aggregate, to payments for multiple source drugs. Until January 1, 2007, the FULs are calculated to be equal to 150% of the published price for the least costly therapeutic equivalent. The published prices

¹⁰ A multiple source drug is a covered outpatient drug for which there are two or more drug products which are therapeutically, pharmaceutically and bio-equivalent and are sold or marketed in the state [1927(k)(7)(A)(i)].

¹¹ 42 CFR 447.331-447.332

that CMS uses as a basis for calculating upper payment limits are the lowest of the “average wholesale prices” for each group of drug equivalents. Average wholesale prices (AWPs), intended to represent the average price at which wholesalers sell a drug product to retail pharmacies, are published annually in compendia by the pharmaceutical industry.¹²

After implementation of DRA 2005, FULs will apply to multiple source drugs (defined to include any drug for which there is at least one other drug sold and marketed during the period that is rated as therapeutically equivalent and bioequivalent to it). For these multiple source drugs, the FUL would be equal to 250% of the “average manufacturer price” (AMP) computed without regard to prompt pay discounts. The AMP is a price reported to CMS by manufacturers, and is calculated to be the average price at which manufacturers sell a drug product to wholesalers.

Under either FUL policy, each state must assure the Secretary that its Medicaid spending for multiple source drugs is in accordance with the upper limits plus reasonable dispensing fees. The effect of this requirement is that, when a lower-cost “generic” equivalent exists for a brand-name drug, a pharmacy will be paid at a price tied to the generic price even if the brand-name drug is actually furnished. The pharmacy, therefore, has a financial incentive to substitute the lower-cost generic equivalent for the brand-name drug.

The upper limit for multiple source drugs does not apply if a physician provides handwritten certification on the prescription that a specific brand is medically necessary for a particular recipient. The brand name would then be dispensed subject to the limits applicable to “other” drugs.

All “other” drugs include brand-name drugs and multiple source drugs for which a specific FUL limit has not been established. The upper limit that applies to “other” drugs is the lower of the estimated acquisition cost (EAC) plus a reasonable dispensing fee or the provider’s usual and customary charge to the general public. The EAC is the state Medicaid agency’s best estimate of the price generally paid by pharmacies and other providers to acquire the drug. States may use another payment method as long as, in the aggregate, a state’s payments for “other” drugs are below the payment levels determined by applying the upper limit for other drugs.

States’ Payment Formulas

While states must ensure that federal matching funds do not pay for drug prices that exceed the upper limits described above, there are no other rules on how states set their payment formulas for drugs. Most states today use payment formulas that are based on the AWP less some percentage (**Table 2**) for most covered drugs, although this may change with the implementation of DRA 2005. The formulas below represent states’ attempt to estimate the true acquisition costs that retailers pay to wholesalers to obtain the pharmaceuticals they sell. While AWPs are used by the

¹² American Druggist First DataBank Annual Directory of Pharmaceuticals (Blue Book), and *Medi-Span’s Pricing Guide*, and Medical Economic’s *Drug Topics Redbook*.

states to estimate those acquisition costs, it is believed that the published AWP's are more like manufacturers' suggested wholesale prices rather than a true measure of the average costs to pharmacies of obtaining pharmaceuticals. In reality, many drug wholesalers compete with each other by offering pharmacies different discounts from AWP, and some pharmacies purchase their drugs directly from the manufacturers, skipping wholesalers entirely.¹³

Table 2. States' Payment Formulas as of March 2005

State	Amount for each prescription
Alabama	WAC+9.2%; AWP-10%
Alaska	AWP - 5%
Arizona	AWP - 15%
Arkansas	AWP - 20% (generic); AWP-14% (brand)
California	AWP - 17%
Colorado	AWP - 35% (generic) or AWP - 13.5%
Connecticut	AWP - 40% (generic); AWP - 12%
Delaware	AWP - 14% (retail); AWP - 16% (LTC and specialty pharmacies)
District of Columbia	AWP - 10%
Florida	Lowest of AWP - 15.45% or WAC + 5.75%
Georgia	AWP - 11%
Hawaii	AWP - 10.5%
Idaho	AWP - 12%
Illinois	AWP - 25%, (generic); AWP - 12% (brand)
Indiana	AWP - 20% (generic); AWP - 13.5% (brand)
Iowa	AWP - 12%
Kansas	AWP - 27% (generic); AWP - 13% (single source)
Kentucky	AWP - 12%
Louisiana	AWP - 13.5%; AWP - 15% for chains
Maine	AWP - 15%; AWP - 17% or usual and customary plus professional fee or FUL/MAC plus professional fee for direct supply drug list; Lower of AWP-20% plus professional fee or usual and customary for mail order*
Maryland	Lower of AWP - 12% or WAC+8%, direct price+8% or distributor price when available.
Massachusetts	WAC + 5%

¹³ E.K. Adams, D.H. Kreling, and K. Gondek, State Medicaid Pharmacy Payments and Their Relation to Estimated Costs, *Health Care Financing Review*, vol. 15, no. 3, Spring 1994, p. 27.

State	Amount for each prescription
Michigan	AWP - 13.5% (1-4 stores); or AWP - 15.1% (5+ stores)
Minnesota	AWP - 11.5%
Mississippi	AWP - 12%
Missouri	Lower of AWP - 10.43% or WAC + 10%
Montana	AWP - 15%
Nebraska	AWP - 11%
Nevada	AWP - 15%
New Hampshire	AWP - 16%
New Jersey	AWP - 12.5%
New Mexico	AWP - 14%
New York	AWP - 12%
North Carolina	AWP - 10%
North Dakota	AWP - 10%
Ohio	Lower of WAC + 9% or AWP - 12.8%
Oklahoma	AWP - 12%
Oregon	AWP - 11% (institutional), or AWP - 15% (non-institutional)
Pennsylvania	AWP - 10%
Rhode Island	WAC + 5%
South Carolina	AWP - 10%
South Dakota	AWP - 10.5%
Tennessee	AWP - 13%
Texas	Lower of AWP - 15% or WAC + 12%
Utah	AWP - 15%
Vermont	AWP - 11.9%
Virginia	AWP - 10.25%
Washington	AWP - 14% [single source and multiple source (1-4 manuf.)], AWP - 50% (multiple source, 5+), AWP - 19% (brand-mail order), AWP - 15% (generic-mail order)
West Virginia	AWP - 12%
Wisconsin	AWP - 11.25%
Wyoming	AWP - 11%

Source: [<http://www.cms.hhs.gov/medicaid/drugs/pre0305.pdf>]

Notes: * For other exceptions see state plan.

AWP: Average Wholesale Price
WAC: Wholesalers Acquisition Cost

Another provision in DRA 2005 requires the Secretary of HHS to make manufacturers' reported AMP data available on a monthly basis to states and to post those amounts, with at least quarterly updates, on a website accessible to the public. The availability of such data, beginning in July 2006, may encourage states to make changes to their drug reimbursement formulas based on AMPs instead of AWP. There are a few reasons why states may want to make this change. First, basing reimbursements on the same measure of price that the FULs are based on will help to ensure that the ceilings are not exceeded. Second, the AMPs, unlike the AWP, will be calculated consistent with regulations that are to be promulgated by the

Secretary of HHS no later than July 1, 2007. In addition, AMPs are subject to the oversight and review of the Secretary of CMS.

Dispensing Fees

Dispensing fees, the amounts paid to pharmacies to cover the cost of dispensing the prescription medication are only limited insofar as they must be “reasonable.” Such fees generally range from under \$3.00 per prescription to just over \$5.00 per prescription, although fees may be higher in states that do not use a flat fee. Until only recently, few states varied professional dispensing fees. Today dispensing fees in many states vary, most often with higher fees paid for generics than for single source drugs. In a few states, the fees vary by urban/rural location or based on the pharmacy’s historical operating cost and volume.

Medicaid Drug Rebates

An important feature of Medicaid’s “best price” drug payment policy was created in the Omnibus Budget Reconciliation Act of 1990. That law requires drug manufacturers that wish to have their drugs available for Medicaid enrollees to enter into rebate agreements with the Secretary of HHS, on behalf of the states. Under the agreements, pharmaceutical manufacturers must provide state Medicaid programs with rebates on drugs paid for Medicaid beneficiaries. The formulas used to compute the rebates are intended to ensure that Medicaid pays the lowest price that the manufacturers offer for the drugs. In return for entering into agreements with the Secretary, state Medicaid programs are required to cover all of the drugs marketed by those manufacturers (with possible exceptions for the 10 categories of drugs that states are allowed to exclude from coverage). In 2003 there were reported to have been more than 550 manufacturers participating in the Medicaid drug rebate program.¹⁴

Rebate requirements do not apply to drugs dispensed by Medicaid managed care organizations when the drugs are paid as part of the MCOs capitation rate, and to drugs provided in hospitals, and sometimes in physicians’, or dentists’ offices, or similar settings.¹⁵ Rebate requirements, on the other hand, do apply to prescription drugs provided on a fee-for-service basis as well as to nonprescription items, such as aspirin, when they are prescribed for a Medicaid beneficiary and covered under the state’s Medicaid plan.

The rebates are computed and remitted by pharmaceutical manufacturers each quarter based on utilization information supplied by the state programs. States collect the rebates from the manufacturers. The federal share of the rebates are subtracted from states’ claims for their federal share of program costs.

¹⁴ Testimony of Dennis Smith, Director, Center for Medicaid and State Operations, Centers for Medicare and Medicaid Services, before the Energy and Commerce Committee, Subcommittee on Oversight and Investigations, December 7, 2004.

¹⁵ The general rule here is that rebates apply to drugs when they are billed separately, and not when their costs are embedded in a claim for another service.

In setting the amount of required rebates, the law distinguishes between two classes of drugs. The first includes single source drugs (generally, those still under patent) and “innovator” multiple source drugs (drugs originally marketed under a patent or original new drug application (NDA) but for which generic competition now exists). The second class includes all other, “non-innovator” multiple source drugs (generics). **Table 3** shows the requirements applicable to the two different classes of drugs. These are discussed in further detail below.

Single Source and “Innovator” Multiple Source Drugs. Manufacturers are required to pay state Medicaid programs a basic rebate for single source and innovator multiple source drugs. Basic rebate amounts are determined by comparing the average manufacturer price (AMP) for a drug (the average price paid by wholesalers) to the “best price,” which is the lowest price offered by the manufacturer in the same period to any wholesaler, retailer, nonprofit, or public entity.¹⁶ The basic rebate is the greater of 15.1% of the AMP or the difference between the AMP and the best price.

Additional rebates are required if the weighted average prices for all of a given manufacturer’s single source and innovator multiple source drugs rise faster than inflation as measured by the consumer price index for all urban consumers. Prices in effect on October 1, 1990 are used as a base and are compared with prices in the month before the start of the period for which the rebate is to be issued to determine if current prices have risen faster than inflation.

The AMP, used to calculate rebates, and the AWP, used by states to set prices for drugs and by the federal government to calculate upper payment limits, each measure pharmaceutical prices but at different stages of the journey from manufacturing plant to individual drug user. The AMP measures prices charged by manufacturers when selling to wholesalers. The AWP measures the prices charged by wholesalers when selling the products to retail pharmacies. The AMP was created in Medicaid statute for the purpose of calculating rebates. The statute further requires that those prices remain confidential. The AWPs are figures that are developed and used by manufacturers and retailers and are shared in the industry in several annual publications. While the numbers are not overtly linked by formula or derivation, economists would assume similar forces would impact the prices at each stage. As estimated by the Office of the Inspector General of Health and Human Services, at the median, AMP is 59% below the AWP. But this median masks large differences based on the type of drug. For single source drugs and multisource brand-name drugs, the median difference is between 23 and 28%. For generic drugs, however, the median AMP is 70% lower than AWP at the median.¹⁷

¹⁶ For the purposes of determining Medicaid rebates, prices paid by a number of federal and state entities are excluded from the definition of the “best price.” These are discussed in further detail below.

¹⁷ U.S. Department of Health and Human Services, Office of the Inspector General, *Medicaid Drug Price Comparisons: Average Manufacturer Price to Published Prices*, OEI-05-05-00240, June 2005. Other comparative pricing analyses can be found in U.S. General Accounting Office, *States’ Medicaid Payments for Prescription Drugs*, GAO-06-69R, Oct.

Since 1990 there have been a few changes to the Medicaid drug rebate policy. Before 1992 “best price” was defined to exclude drugs sold to federal agencies at depot prices¹⁸ and single award contract prices. Under the Veterans Health Care Act of 1992 (P.L. 102-585) prices charged by manufacturers to certain federal agencies were also excluded from the determination of “best price.” These agencies include the Department of Veteran’s Affairs (DVA), the Department of Defense (DOD), the Public Health Service (PHS) and various PHS-funded health programs, and state (non-Medicaid) pharmaceutical assistance programs. The exclusion of those prices from the “best price” potentially reduced Medicaid savings from the rebate program, so Congress responded with a potential offset. Rebate percentages were increased to those amounts shown in **Table 3**. MMA 2003 further excludes prices of drugs to be provided under Medicare Part D once the program is implemented. This time no offsetting rebate adjustment was made.

The Veteran’s Health Care Act also provides, as a condition of Medicaid reimbursement for a manufacturer’s drugs, that the manufacturer enter into a separate agreement with the Secretary to provide discounts and rebates to certain PHS-funded entities with public disproportionate share hospitals, as well as a new discount agreement with DVA.¹⁹

“Non-Innovator” Multiple Source Drugs. For non-innovator multiple source drugs, basic rebates are equal to 11% of the AMP. Prices offered to other payers are not considered, nor is there any additional rebate for excess price increases.

¹⁷ (...continued)

2005, and U.S. Congressional Budget Office, *How the Medicaid Rebate on Prescription Drugs Affects Pricing in the Pharmaceutical Industry*, Jan. 1996.

¹⁸ Depot prices are the prices paid for drugs procured through federal distribution systems and warehoused at federal facilities (depots).

¹⁹ Even before the Veterans Health Care Act of 1992, the DVA had been negotiating discounted prices with manufacturers for drugs provided at DVA and other military facilities.

Table 3. Medicaid Rebate Formulas

	Single source and “innovator” multiple source drugs	“Non-innovator” multiple source drugs
Basic rebate	The greater of: 15.1% of the AMP or AMP minus best price	11% of the AMP
Additional rebate	Required if the drug product price rises faster than inflation as measured by the CPI-U	N/A

Source: Section 1927(c) of the Social Security Act.

In 2004, the total amount of federally required drug rebates was reported by states to be \$8.8 billion. (States also reported collecting more than \$.8 billion in supplemental rebates not required by the federal government, although there is reason to believe that reported amounts for state supplemental rebates are too low. See the discussion on page 14.) On average, federal rebates represented about 22% of Medicaid spending on outpatient prescription drugs. Rebates for 2004 by state are reflected in **Table 4**.

Table 4. Medicaid Total Drug Spending and Rebates by State, 2004

(in millions of dollars, includes state and federal shares)

State	Total spending on prescription drugs	Federal rebates collected	Spending net of federal rebates	Federal rebates as percentage of drug spending
Alabama	594.5	126.7	467.8	21%
Alaska	115.3	29.2	86.1	25%
Arizona	5.4	—	5.4	—
Arkansas	380.4	82.3	298.2	22%
California	4817.6	1079.0	3738.6	22%
Colorado	264.1	60.3	203.9	23%
Connecticut	448.2	96.6	351.5	22%
Delaware	122.6	25.1	97.5	20%
Dist. Of Col.	106.5	20.5	85.9	19%
Florida	2,472.8	565.0	1,907.8	23%
Georgia	1,213.8	252.2	961.6	21%
Hawaii	117.1	27.8	89.4	24%
Idaho	153.4	29.9	123.5	19%
Illinois	1,751.6	393.6	1,358.1	22%
Indiana	703.9	177.4	526.6	25%
Iowa	371.9	84.8	287.2	23%
Kansas	274.2	65.4	208.8	24%
Kentucky	802.7	169.3	633.4	21%
Louisiana	944.2	187.6	756.5	20%
Maine	281.7	80.2	201.6	28%
Maryland	490.3	90.6	399.6	18%
Massachusetts	987.3	277.1	710.2	28%
Michigan	874.7	239.1	635.6	27%

State	Total spending on prescription drugs	Federal rebates collected	Spending net of federal rebates	Federal rebates as percentage of drug spending
Minnesota	394.6	92.2	302.4	23%
Mississippi	668.1	125.4	542.7	19%
Missouri	1,119.7	220.6	899.1	20%
Montana	99.3	20.8	78.6	21%
Nebraska	231.3	46.6	184.7	20%
Nevada	127.9	28.9	99.0	23%
New Hampshire	128.6	33.2	95.3	27%
New Jersey	1,016.6	197.5	819.2	19%
New Mexico	117.4	24.5	92.9	21%
New York	4,782.6	962.5	3,820.1	20%
North Carolina	1575.0	324.7	1250.3	21%
North Dakota	59.7	14.1	45.7	24%
Ohio	1,819.6	407.9	1,411.7	22%
Oklahoma	416.3	74.2	342.1	18%
Oregon	245.2	53.8	191.3	22%
Pennsylvania	952.3	196.4	755.9	21%
Rhode Island	166.1	38.1	128.0	23%
South Carolina	673.0	163.6	509.4	24%
South Dakota	81.9	17.6	64.4	21%
Tennessee	2,196.1	461.9	1,734.1	21%
Texas	2,202.1	507.4	1,694.7	23%
Utah	192.1	45.8	146.3	24%
Vermont	160.0	34.2	125.8	21%
Virginia	582.1	134.8	447.3	23%
Washington	649.3	148.1	501.2	23%
West Virginia	376.4	92.8	283.6	25%
Wisconsin	684.9	162.0	522.9	24%
Wyoming	52.8	11.9	40.9	23%
Total	40,071.5	8,801.2	31,270.2	22%

Source: Table prepared by Congressional Research Service (CRS) based on tabulations of 2004 CMS Financial Management Reports.

* Arizona has a statewide managed care waiver in place. Under the waiver, all Medicaid services are provided through capitated arrangements. Since drugs are included in the capitation payment to MCOs, rebates do not apply.

Drug Pricing and Rebate Issues

Average Wholesale Prices. The DRA 2005 has addressed a concern that had been raised repeatedly in the last several years regarding the AWP and the states' and HHS's reliance on those prices for setting pharmaceutical payment levels and FULs. The concern that the AWP do not reflect the intended wholesale prices, and that manufacturers purposely manipulate the published AWP to offer discounts to certain purchasers without offering those prices to Medicaid has been studied by Congress, the General Accounting Office, and the office of the Inspector General (IG) of Health and Human Services (HHS).²⁰ By replacing the FUL computation with a formula based on AMPs, the use of AWP for setting Medicaid drug prices

²⁰ U.S. Congress, House Committee on Government Reform, Correspondence to Representative Henry A. Waxman, Ranking Minority member, from June Gibbs Brown, Inspector General, Dept. of Health and Human Services, Nov. 22, 1999.

may become a thing of the past. In addition, DRA 2005 allows the Secretary to gather data on retail drug prices. This data may prove to be useful for determining whether the upper limits on drug prices are too high, too low, or adequate.

Circumventing the Best Price or Rebate Policies. A second area that has raised concerns having to do with Medicaid drug pricing issues relates to the best prices that are reported by manufacturers to CMS and are used by CMS to calculate rebates. There have been cases in which manufacturers sell drugs or report drug prices in ways that circumvent Medicaid's rebate requirement or minimize rebates to be paid. For example, manufacturers could skirt the best price requirement by selling finished drugs to certain favored HMOs at large discounts and claiming that they have been sold to "repackagers" or "redistributors." Since drugs sold by repackagers or redistributors are not subject to Medicaid's rebate requirements, rebates are avoided. In 1999, the Inspector General estimated the lost rebate for one repackaged drug at over \$25 million in one year.²¹ In addition, recently, Schering Plough Corporation agreed to pay \$293 million to resolve its liabilities in connection with fraudulent pricing of its allergy drug Claritin under the Medicaid drug rebate program. Schering Plough allegedly failed to include the value of certain incentives offered to two managed care organizations in the best price reported for purposes of the Medicaid drug rebate program. The resulting charge was that Medicaid rebates were underpaid, and other entities (such as community health centers) that purchase drugs at ceiling prices that are based on Medicaid drug rebate prices were overcharged.²²

DRA 2005 intervened to address another concern related to the collection of rebates on certain drugs. The IG and CMS have both raised the concern that some rebates have gone unpaid for certain drugs administered by physicians in their offices (or in another outpatient setting), such as chemotherapy, simply due to operational gaps. This is because providers use Healthcare Common Procedure Coding System (HCPCS) J-codes to bill the Medicaid program for injectible prescription drugs, including cancer drugs. The HCPCS J-codes do not, however, provide states with the specific manufacturer information necessary to enable them to seek rebates. In a letter to state Medicaid directors, CMS requested that states identify Medicaid drugs, specifically those using HCPCS J-codes, by their NDC codes so that rebates can be collected for these drugs (SMDL #03-002, dated March 14, 2003). Nonetheless, DRA 2005 stepped in to require, as a condition of receiving Medicaid payments, that states submit to the Secretary of HHS utilization data and coding information for certain physician-administered outpatient drugs. Such data would be required initially for all single source drugs administered by physicians. Later, the same data would be required for the 20 physician-administered multiple source drugs with the highest dollar volume as determined by the Secretary.

²¹ Correspondence from the Office of the Inspector General, Nov. 1999.

²² Testimony of George M. Reeb, Assistant Inspector General for the Centers for Medicare and Medicaid Audits, Office of Inspector General, U.S. Department of Health and Human Services before the Energy and Commerce Committee, Subcommittee on Oversight and Investigations, December 7, 2004.

Finally, the DRA included a provision intended to improve best price reporting for authorized generic drugs. Sometimes manufacturers produce both a brand-name version of a prescription drug and also sell or license a second manufacturer (or a subsidiary) to produce some of the same product to be sold or re-labeled as a generic. Concerns have been raised by two Senators, both in a letter to the Chairman of the Federal Trade Commission²³ and at a hearing on Medicaid fraud²⁴ that there may be problems collecting rebates on these generic products, referred to as “authorized generics.” One potential problem is that the reported best prices for the brand-name product do not properly account for prices at which the authorized generics are sold. A second potential problem is that the rebates for the authorized generics are calculated using the wrong rebate formula.

The DRA 2005 modified the existing drug price reporting requirements to ensure, effective January 1, 2007, that the manufacturer-reported prices, including both the average manufacturer’s price and the manufacturer’s best price, include the price of the authorized generic.²⁵ In addition, the IG has included, in the agency’s work plan for 2006, an investigation of rebates for authorized generic products.²⁶

Supplemental Rebates. In addition to the rebates required under federal law, a number of states charge certain pharmaceutical manufacturers additional rebates. In 2004, 15 states claimed a total of \$851 million in supplemental rebates (federal share of \$474 million).²⁷ California collected 63% of the total reported amounts. But reported collections are likely to be too low. In information provided by CMS to the Committee on Energy and Commerce, 37 states are noted to have supplemental rebates in effect. If true, supplemental rebate collections may well exceed the amount reported in the 2004 CMS Financial Management Reports.

Controlling Drug Cost and Use

Prior Authorization. States use a number of techniques to control cost and/or use of pharmaceuticals. One of those techniques is prior authorization. Under a prior authorization requirement, only those pharmaceutical products that have been approved in advance by a designated individual or entity are covered. States may establish prior authorization programs under Medicaid for all drugs or for certain classes of drugs, as long as these programs meet two criteria: (1) they must respond

²³ Letter dated May 9, 2005 from Senators Grassley and Rockefeller to Federal Trade Commission Chairman Deborah Platt Majoras posted at [<http://www.Grassley.Senate.Gov>].

²⁴ U.S. Congress, House Committee on the Energy and Commerce, Subcommittee on Oversight and Investigations, *Medicaid Prescription Drug Reimbursement: Why the Government Pays Too Much*, hearings, 108th Cong., 2nd sess., Dec. 7, 2004, H.Rept. 108-126 (Washington: GPO, 2004).

²⁵ The bill language doesn’t use the term “authorized generic.” Instead it requires the reported prices to include the price of any drug sold under a new drug application approved (under Section 505c of the Federal Food, Drug and Cosmetic Act, FFDC) by FDA.

²⁶ See [<http://www.oig.hhs.gov/publications/docs/workplan/2006/WorkPlanFY2006.pdf>], p. 27.

²⁷ Supplemental rebates are required to be shared by states and the federal government in the same way that federally required rebates are shared.

within 24 hours to a request for approval, and (2) they must dispense at least a 72-hour supply of a covered drug in emergency situations. In 2004, all (including the District of Columbia) but one state reports having a prior authorization procedure for at least some covered drugs, but little information is available describing the number or types of drugs those states require to undergo such review.²⁸

Some pharmaceutical industry representatives and consumer advocates have voiced opposition to states' use of prior authorization programs. They claim such programs are burdensome, are not cost effective, and are becoming increasingly restrictive. In addition, there are concerns that states are adding more and more drugs to lists of those that require prior authorization and that such requirements are particularly problematic for individuals who need newly developed drugs, possibly because reviewers are less familiar with those drugs. Prior authorization is reportedly particularly problematic for persons needing psychotherapeutics, a population for whom compliance with drug therapies is often challenging to achieve even without additional administrative barriers.

Prescribing/Dispensing Limitations. States may also restrict the quantity of prescription drugs available to beneficiaries. Such prescribing and dispensing limits are ubiquitous. All but two states surveyed for the National Pharmaceutical Council (NPC) indicated the use of prescribing or dispensing limits (**Table 5**). The most common type of constraint is on the quantity of drug that may be made available for each prescription. Almost all of the states routinely limit the amount of certain drugs dispensed to a 30- to 34-day supply.

²⁸ National Pharmaceutical Council, 2004.

Table 5. Medicaid Drug Prescription or Dispensing Limits, 2004

State	Limits on number, quantity, and refills of prescriptions
Alabama	30-day supply per Rx, 5 refills per Rx, 4 brand limit per month
Alaska	30-day supply per Rx, other ceilings on certain classes of drugs
Arizona	**
Arkansas	31-day supply per Rx, 3 Rx per month (extension to six), five refills per Rx within 6 months
California	Six Rx per month, maximum 100 day supply for most meds.
Colorado	30-day supply per Rx, reasonable amounts for maintenance medication, other limits may apply
Connecticut	240 units or 30-day supply, 5 refills except for oral contraceptives
Delaware	34-day supply or 100 unit doses per Rx (whichever is greater)
District of Columbia	30-day supply per Rx, 3 refills per Rx within 4 months, other limits specific to certain medications
Florida	4 brand-name Rxs per month (with exceptions)
Georgia	34-day supply per Rx, 5 Rx per month (adult), 6 Rx per month (child); \$2999.99/Rx limit (potential override)
Hawaii	30-day supply or 100 unit doses per Rx, maximum quantities for some drugs.
Idaho	34-day supply (with exceptions), 3 cycles birth control, limits on refills
Illinois	Medically appropriate monthly quantity
Indiana	—
Iowa	Maximum 30-day supply except select maintenance drugs (90 days)
Kansas	31 day supply per RX, 5 Rx per month, other limitations specific to certain medications
Kentucky	30 day supply, Maximum 5 refills in six months, one dispensing fee per month for maintenance medication
Louisiana	Greater of 30-day supply per Rx or 100 unit doses, 5 refills per Rx within six months, max 8 Rx per recipient per month
Maine	34-day supply (brand), 90-day supply (generic), maximum 11 refills per Rx, 5 brand Rx per month
Maryland	34-day supply per Rx, 11 refills per Rx, refills cannot exceed 360-day supply
Massachusetts	30-day supply, 11 refills per Rx
Michigan	100-day supply, quantity limits for certain drugs
Minnesota	34-day supply
Mississippi	Greater of 34-day supply or 100 unit doses per Rx, 5 Rx per month, 11 refills maximum
Missouri	—
Montana	34-day supply
Nebraska	Greater of 90-day supply or 100 dosage units per Rx, five refills per Rx, 6 mo. for controlled substances, 31 days for injectibles
Nevada	34-day supply per Rx, 100 day supply for maintenance medications, 5 refills within 6 months
New Hampshire	30-day supply, 90-day supply on maintenance medications
New Jersey	34-day supply or 100-unit dosage per Rx, 5 refills within 6 months

State	Limits on number, quantity, and refills of prescriptions
New Mexico	34-day supply except contraceptives (100 days) and maintenance drugs (90 days)
New York	5 refills per Rx, annual limits on number of Rx and OTC drugs available (with exceptions)
North Carolina	34-day supply per Rx, with exceptions, 6 Rx per month
North Dakota	34-day supply per Rx, max 12 refills per script, other limits on refills based on class of drug
Ohio	34-day supply; 102 day supply for maintenance, 5 refills per Rx
Oklahoma	34-day supply or 100 unit doses per Rx, 6 Rx per month (age 21 and over, under 21 unlimited)
Oregon	34-day supply, 15-day supply for initial Rx for chronic conditions, duration limits on selected drugs
Pennsylvania	Greater of 34-day supply or 100 unit, 5 refills within 6 months, 6 Rx per month
Rhode Island	30-day supply per Rx (non-maintenance), 5 refills per Rx
South Carolina	34-day supply w/ unlimited Rx (children), 4 Rx per month (adult) with exceptions
South Dakota	Varies by drug
Tennessee	31-day supply, 1 year for non-controlled medications
Texas	3 Rx per month, unlimited Rx for nursing home residents and children, max 5 refills, cumulative limit on specific drugs
Utah	31-day supply per Rx, max 5 refills per Rx, other limits on specific drugs
Vermont	60-day supply for maintenance medications, 5 refills per Rx
Virginia	34-day supply per Rx
Washington	34-day supply per Rx, usually 2 refills per month, 4 refills for antibiotics or scheduled drugs
West Virginia	34-day supply, 11 refills per Rx with quantity limits on some drugs
Wisconsin	34-day supply per Rx with exceptions, maximum 11 refills during 12-month period
Wyoming	Quantity limits on some medications as deemed clinically appropriate

Source: National Pharmaceutical Council, Pharmaceutical Benefits Under State Medical Assistance Programs 2004.

Notes: Rx: Prescription

** Within federal and state guidelines, individual managed care and pharmacy benefit management organizations make formulary/drug decisions.

Drug Use Review. All states use policies to control the use of outpatient prescription drugs and all have programs in place to assess the quality of their pharmaceutical programs. The Omnibus Budget Reconciliation Act of 1990 included a requirement that all states implement drug use review (DUR) programs, and provided for enhanced federal matching payment to cover the costs of conducting those DUR activities. DUR programs are aimed at both improving the quality of pharmaceutical care and assisting in containing costs. The major features of DUR programs are: enhanced communication between pharmacists and beneficiaries upon

dispensing prescriptions; ongoing retrospective review of prescribing practices; educational outreach for pharmacists, physicians, and beneficiaries; and pharmacy counseling.

Cost Sharing Requirements for Medicaid Prescription Drugs. In addition to prior authorization and utilization review, many Medicaid programs impose cost sharing requirements on enrollees to control drug use and spending. Cost sharing is another area that the DRA 2005 made significant changes that could affect prescription drug benefits for Medicaid beneficiaries. Under current (pre-DRA 2005) cost sharing limitations, states are prohibited from requiring copayments on services provided to children under age 18, pregnant women for any services that relate to the pregnancy or to any medical condition that may complicate pregnancy; and people who are hospitalized or residing in a long-term care facility. In addition, copayments cannot be charged for people receiving hospice, emergency²⁹ and family planning services. Within those guidelines, states may, and most do, impose “nominal” cost sharing amounts on other users of drug benefits.³⁰ States that require copayments for covered outpatient drugs generally charge between \$.50 and \$3.00 per prescription — most falling at about \$1.00 per prescription (**Table 6**).

Table 6. Cost Sharing Requirements for Medicaid Pharmaceuticals as of March 2005

State	Amount for each prescription
Alabama	\$.50 to \$3.00
Alaska	\$2.00
Arizona ^a	—
Arkansas	\$.50 to \$5.00
California	\$1.00
Colorado	\$.75 (generic); \$3.00 (brand)
Connecticut	\$1.00
Delaware	None
District of Columbia	\$1.00
Florida	2.5% of payment up to \$300
Georgia	\$.50 (generic, preferred); \$.50 to \$3.00 (brand)
Hawaii	None
Idaho	None
Illinois	none for generic; \$3.00 (brand)
Indiana	\$3.00

²⁹ States may obtain a waiver of this rule to impose up to twice the nominal amount established for outpatient services for services received at a hospital emergency room, if the services are not emergency services, as long as they have established to the satisfaction of the Secretary that beneficiaries have alternative sources of non-emergency, outpatient services that are available and accessible.

³⁰ DRA 2005 changed the definition of “nominal” amounts so that beginning with FY2006, those amounts, as established in regulations CFR Chapter IV, Section 447.54, will be indexed by inflation (as estimated using the medical care component of the consumer price index.)

State	Amount for each prescription
Iowa	\$1.00
Kansas	\$3.00
Kentucky	\$1.00
Louisiana	\$.50 to \$3.00
Maine	\$2.50 (generic and brand); \$3.00 per day in rural health clinics-All subject to ceilings
Maryland	\$1.00-\$2.00
Massachusetts	\$1.00-\$3.00
Michigan	\$1.00 (generic); \$3.00 (brand)
Minnesota	\$1.00 (generic); \$3.00 (brand)
Mississippi	\$1.00 (generic); \$2.00 (preferred brand); \$3.00 (brand)
Missouri	\$.50 to \$2.00
Montana	\$1.00
Nebraska	\$2.00
Nevada	\$1.00 (generic); \$2.00 (brand)
New Hampshire	\$1.00 (generic); \$2.00 (brand & compound)
New Jersey	None
New Mexico	None
New York	\$.50 (generic); \$2.00 (brand)
North Carolina	\$1.00 (generic); \$3.00 (brand)
North Dakota	\$3.00 (brand)
Ohio	\$3.00 (non-preferred)
Oklahoma	\$1.00 to \$2.00
Oregon	\$2.00 (generic); \$3.00 (brand)
Pennsylvania	\$1.00
Rhode Island	None
South Carolina	\$3.00
South Dakota	\$2.00
Tennessee*	—
Texas	None
Utah	\$3.00
Vermont	\$1.00 to \$3.00
Virginia	\$1.00
Washington	None
West Virginia	\$.50-\$3.00
Wisconsin	\$.50 (over the counter); \$1.00 (generic) \$3.00 (brand)
Wyoming	\$2.00

Source: [<http://www.cms.hhs.gov/medicaid/drugs/pre0305.pdf>].

Notes:

* Within federal and state guidelines, individual managed care and pharmacy benefit management organizations make formulary/drug decisions.

DRA 2005 created two optional cost sharing plans that states could choose to implement as alternatives to the cost sharing limitations described above. Under the new cost sharing options, both of which will become effective on March 31, 2006, states are prohibited from requiring cost sharing for certain Medicaid beneficiaries. The list of those that must remain exempt from cost sharing is slightly different from

the list of those exempt under prior law. States will be prohibited from imposing cost sharing for (1) services provided to mandatory children who are under age 18 or are in foster care under Part B of Title IV, or are receiving adoption or foster care assistance under Title IV-E regardless of age; (2) preventive services provided to children under 18 regardless of family income; (3) services provided to pregnant women that relate to pregnancy or to other medical conditions that may complicate pregnancy; (4) services provided to terminally ill individuals receiving Medicaid hospice; (5) services provided to individuals in medical institutions who are required to spend their income down to qualify for Medicaid; (6) emergency services; (7) family planning services and supplies; and (8) services provided to women qualifying for Medicaid under the breast and cervical cancer eligibility group.

The first new cost sharing option under DRA 2005 allows states to establish cost sharing amounts that exceed nominal amounts and to vary those amounts among classes or groups of individuals or by types of services. The second option, which applies specifically to outpatient prescription drugs, allows states to establish a cost sharing plan under which beneficiaries are charged higher cost sharing amounts for state-identified non-preferred drugs, and no or reduced cost sharing amounts for preferred drugs.

The two new options come with additional limitations. Besides the groups that are specifically exempted, as described above, the DRA 2005 cost sharing amounts cannot exceed 10% of the cost of the item or service for individuals with income between 100% and 150% of poverty, and 20% of the cost of the item or service for individuals with an income over 150% of poverty. In addition, an aggregation of all cost sharing amounts cannot exceed 5% of family income.

Other Cost Containment Strategies. Some states are attempting to manage drug costs through the use of pharmaceutical benefits managers (PBMs). Many private insurers, including those that provide coverage to federal employees under the Federal Employees Health Benefits Program (FEHBP), contract with PBMs for drug benefits management and claims payment. PBMs enable insurers to obtain discounts for pharmaceuticals that would not otherwise be available to single insurers because the PBMs administer multiple insurers' covered populations. In addition, PBMs provide a variety of administrative services intended to improve quality and control costs, such as retail pharmacy network development, mail order pharmacy operation, formulary development, manufacturer rebate negotiation and prescription checks for adverse drug interactions.³¹ While PBMs have begun to administer a significant portion of the market for private prescription drug benefits, they are not broadly used by states in administering Medicaid drug benefits.

Bulk Purchasing Programs. A number of states have considered establishing bulk purchasing programs for outpatient prescription drugs. Bulk purchasing can be used to obtain those drugs required by state Medicaid agencies combined with those needed by other in-state agencies such as state employees' plans and local governments or could combine the prescription drug needs of two or more

³¹ GAO/HEHS-97-47; Pharmacy Benefit Managers; FEHBP Plans Satisfied With Savings and Services, but Retail Pharmacies Have Concerns, Feb. 1997.

states together. While many states are considering such programs, few have actually been implemented and evidence of savings based on these purchasing arrangements among the few implemented purchasing arrangements are scarce. This is because most programs are implemented along with other changes to the formularies and/or the management of pharmaceutical benefits, making isolating the impact of the bulk negotiating power very difficult.

Two Medicaid purchasing pools are in place today. Five states have joined forces to negotiate for lower prescription drug prices.³² Michigan, Vermont, New Hampshire, Alaska, and Nevada comprise a joint purchasing pool for Medicaid drugs that has been operating since 2004. Each state has estimated 2004 savings to the Medicaid program that range from \$250,000 in New Hampshire to \$8 million in Michigan. Other states reportedly plan to join that pool. Georgia established a purchasing program for its state prescribing needs that combines Medicaid outpatient drugs with those needed for public employees and university employees. The program which combines bulk purchasing with plan design changes and a preferred drug list, is claimed to have reduced “pharmacy cost trends” by 18 to 25%.³³ While relatively little bulk purchasing is under way today, it is likely that this approach will continue to gather attention in the coming years as states seek ways to control Medicaid costs.

Importing Lower-Priced Drugs from Canada. Several state and local governments are currently considering plans to reimport prescription drugs from Canada in order to save money on medicines that they reimburse for or provide to residents and/or employees. For example, states such as California, Iowa, Illinois, Minnesota, and New Hampshire have begun exploring the prospect of drug importation, and at least two localities, Springfield, Massachusetts and the city of Montgomery Alabama, have already begun to import drugs for employees and retirees.³⁴ These states or other units of government argue that they have a duty to explore innovative methods for providing more affordable prescription drugs to their residents, even at the risk of violating federal law. Each state and local importation plan varies in their details — at least one includes pharmaceuticals for Medicaid recipients, but most do not. At this time there are no reimportation programs in operation for Medicaid beneficiaries, although this may change. A provision in MMA 2003 requires the Secretary of HHS to promulgate regulations allowing pharmacists and wholesalers to reimport pharmaceutical products once the Secretary certifies to Congress that such reimported drugs provide no risk to the public’s health and safety and will result in a significant reduction in cost to the American consumer (MMA 2003, Section 1121).

³² See HHS press release at [<http://www.hhs.gov/news/press/2004pres/20040422.html>].

³³ “Aggregate Purchasing of Prescription Drugs: The Massachusetts Analysis,” Heinz Family Philanthropies, Sept. 11, 2001.

³⁴ Gloria Gonzalez, “Cities Vow to Maintain Canadian Rx Reimports,” *Business Insurance*, Feb. 2, 2004, vol. 38, issue 5.

Medicaid Spending for Outpatient Prescription Drugs

Total Medicaid payments for outpatient prescription drugs represent a growing portion of Medicaid spending. In 1990, states reported total payments for outpatient prescription drugs of about \$4.6 billion, or just over 6% of total program spending. In 2004, total payments for Medicaid outpatient prescription drugs, net of all rebates — federal and state — was \$30.4 billion, accounting for about 10.8% of payments for all Medicaid services.³⁵ The average annual growth in drug spending under Medicaid over the 13- year period was about 14.4% per year.

Despite the large and growing share of Medicaid spending on drugs, those numbers represent only a portion of true Medicaid drug spending. States do not include the cost of outpatient prescription drugs provided through capitated arrangements in their reports. In 1990, this probably did not present a major gap in the available information about Medicaid drug spending since only about 10% of Medicaid enrollees received coverage through capitated managed care arrangements. Today, however, well over one-half of Medicaid’s enrollees receive some or all of their benefits through Medicaid managed care organizations or prepaid health plans. In addition, other prescription drug payments for products purchased directly from physicians or included in claims for other services, such as institutional and home health care, are not reported as outpatient drug spending.

Table 7. Total Medicaid Spending and Medicaid Prescription Drug Spending and Percentage Change in Spending for Selected Years
(in billions of dollars)

Year	Total Medicaid benefits spending ^a	Average annual percentage change	Medicaid prescription drug spending ^b	Average annual percentage change
1990	\$ 72.5	—	\$ 4.6	—
1995	\$ 151.8	15.9%	\$ 8.4	12.7%
2000	\$195.5	5.2%	\$16.6	14.7%
2004	\$281.8	9.6%	\$30.4	16.4%

Source: Table prepared by Congressional Research Service (CRS) based on tabulations from HCFA Form 64/ CMS Form 64 data and Financial Management Reports.

- a. Does not include administrative costs.
- b. Does not include prescription drugs paid through capitated arrangements, obtained directly from physicians or bundled in claims for other services, and federal and state rebates have been subtracted from totals.

Medicaid Drug Spending by State. Table 8 shows 2004 Medicaid spending for prescription drugs by state in order, beginning with the state with the largest percentage of program spending for prescription drugs. (Amounts in Table 8 are total reported payments for outpatient prescription drugs minus rebates.)

³⁵ CRS tabulation of 2004 Medicaid Financial Management Reports.

Medicaid drug spending as a percentage of total Medicaid medical assistance spending varies widely. About 25.7% of Medicaid spending in Tennessee is attributed to outpatient prescription drugs. New Mexico spends the smallest percentage of program spending on outpatient drugs — about 3.3%. While wide variation in drug spending exists across states, in the past Medicaid was claimed to be the single largest payer for outpatient prescription drugs within each state.³⁶

New York reported spending the largest amount on Medicaid outpatient prescription drugs — almost \$3.8 billion in 2004. Wyoming, the state with the smallest Medicaid enrollment, reported the lowest amount of outpatient prescription drug spending — \$40.9 million, in 2004.

³⁶ Institute for Health Services Research, Apr. 1995.

**Table 8. Total Medicaid Spending and
Outpatient Drug Spending, 2004**
(payments in millions of dollars)

State	Drug spending as percentage of all medical assistance	Outpatient Drug spending	Medical assistance Spending
Tennessee	25.7%	1,734.1	7,029.8
Mississippi	16.5%	542.7	3,284.7
Vermont	15.8%	125.8	798.8
North Carolina	15.7%	1,250.3	7,945.6
Kentucky	15.5%	633.4	4,086.4
Louisiana	15.3%	756.5	4,933.0
Florida	14.9%	1,907.8	12,790.0
Missouri	14.8%	899.1	6,082.5
West Virginia	14.6%	283.6	1,937.3
Oklahoma	13.7%	342.1	2,500.5
Georgia	13.7%	961.6	7,044.1
Illinois	13.6%	1,358.1	9,991.3
South Carolina	13.2%	509.4	3,848.4
Idaho	13.2%	123.5	938.7
Nebraska	12.9%	184.7	1,430.8
Alabama	12.9%	467.8	3,636.8
Iowa	12.8%	287.2	2,239.3
Delaware	12.3%	97.5	792.0
Ohio	12.2%	1,411.7	11,550.5
California	12.2%	3,738.6	30,677.3
Wisconsin	11.9%	522.9	4,410.9
Utah	11.8%	146.3	1,235.6
Montana	11.8%	78.6	666.6
Kansas	11.7%	208.8	1,782.4
Virginia	11.7%	447.3	3,825.2
Arkansas	11.5%	298.2	2,585.1
South Dakota	11.5%	64.4	561.6
Wyoming	11.2%	40.9	365.8
Indiana	10.8%	526.6	4,889.3
Texas	10.5%	1,694.7	16,077.7
New Jersey	10.3%	819.2	7,928.4
Maine	10.0%	201.5	2,021.2
Hawaii	9.8%	89.3	908.0
Alaska	9.7%	86.1	884.0
Washington	9.6%	501.2	5,243.6
Nevada	9.5%	99.0	1,037.9
North Dakota	9.5%	45.7	479.7
New York	9.3%	3,820.1	40,978.5
Connecticut	9.1%	351.5	3,875.7
Maryland	8.7%	399.6	4,586.4
New Hampshire	8.3%	95.3	1,148.6
Massachusetts	8.1%	710.2	8,725.1
Rhode Island	7.8%	128.0	1,646.3
Michigan	7.7%	635.6	8,224.9
Dist. Of Col.	7.7%	85.9	1,116.0
Colorado	7.7%	203.9	2,648.6
Oregon	7.7%	191.3	2,596.3

State	Drug spending as percentage of all medical assistance	Outpatient Drug spending	Medical assistance Spending
Minnesota	5.4%	302.4	5,550.2
Pennsylvania	5.4%	755.9	14,088.4
New Mexico	4.2%	92.9	2,212.8
Arizona*	—	—	4,933.1
Total	11.1%	31,270.2	281,794.7

Source: Table prepared by Congressional Research Service (CRS) based on tabulations of 2004 CMS Form Financial Management Reports.

Notes: Outpatient drug spending is net of rebates. Does not include outpatient drug spending for Medicaid beneficiaries enrolled in some managed care organizations, payments for products purchased directly from physicians, or payments included in claims for other services such as institutional care.

* Arizona has a statewide managed care waiver in place and does not report outpatient prescription drug expenditures separately.

Spending by Eligibility Group. The Medicaid Statistical Information System (MSIS — the only source of state reported data that identifies spending by eligibility group) shows states spending on drugs in 2003, the latest year for which all 50 state reports are available, of \$32.2 billion spent on outpatient prescription drugs. Of that amount, states reported a total of about \$18.2 billion, or about 56% for individuals qualifying for Medicaid on the basis of being blind or having a disability, almost 25% (\$7.9 billion) for elderly individuals, just more than 9% (\$3.0 billion) on non-disabled and foster care children and an additional 9% (\$2.9 billion) on adults in families with dependent children.^{37, 38}

Table 9 shows average Medicaid prescription drug spending among Medicaid prescription drug users by eligibility group. The data do not reflect spending for those who receive prescription drugs through managed care only, but they do provide a general idea of the relative spending among different groups of beneficiaries.³⁹

³⁷ Expenditures in this paragraph are those reported by states through the Medicaid Statistical Information System (MSIS) for FY2003. Those data do not match expenditures reported above in Tables 4 and 8 (based on CMS-64 reports) for two reasons; because Tables 4 and 8 are for FY2004; and because data reported on form CMS 64 have always varied slightly from the MSIS reported totals. Because the CMS 64 reports are filed for financial accounting purposes, they are generally considered to be a more accurate accounting of total outlays, and are preferred when examining state and/or federal totals. Those data, however do not allow for analysis of spending and use of services for individual and groups of individuals. For those kind of analysis, data from the MSIS system are used.

³⁸ For additional state-by-state data on Medicaid prescription drug spending for dual eligibles, see CRS Report RL31987, *Dual Eligibles: Medicaid Expenditures for Prescription Drugs and Other Services*, by Karen Tritz and Megan Lindley.

³⁹ If per-person drug spending under managed care (which is not shown separately in MSIS data) differs significantly from per-person drug spending under FFS (which is shown separately in MSIS data), the estimates provided here could be somewhat distorted. Since

(continued...)

Among all Medicaid prescription drug users in FY2003, the average Medicaid prescription drug spending amount was \$1,118. Children had the lowest average spending, while blind and disabled enrollees had the highest. Among blind and disabled enrollees with prescription drug spending, the average amount was \$3,060. Among children with prescription drug spending, the average amount was \$229.

Table 9. Average Medicaid Prescription Drug Spending Among Medicaid Prescription Drug Users by Basis of Eligibility, FY2003

	Number of Medicaid enrollees	Percentage of Medicaid enrollees with prescription drug spending	Average Medicaid drug spending per Medicaid prescription drug user
Aged	5,101,111	65.0%	\$2,399
Blind/Disabled	8,405,098	70.7%	\$3,060
Child*	27,285,057	47.5%	\$229
Adult	14,352,033	45.6%	\$445
BCCA women	13,344	60.7%	\$1,732
Total**	55,157,774	52.2%	\$1,118

Source: Congressional Research Service (CRS) tabulations of data from CMS MSIS State Summary Datamart.

Notes: Does not include drug rebates or payments for drugs purchased directly from physicians or included in claims for other services such as institutional care. Since it is generally included in the capitation payment for managed care (not broken out separately), figures on prescription drug users and spending do not include those who receive prescription drugs through managed care only.

* Includes foster care children.

** Total does not sum because this figure includes enrollees for whom basis of eligibility was unknown.

Number and Cost of Prescriptions Filled. In 2003, Medicaid agencies reported processing more than 562 million prescriptions. The average cost of a prescription for the same year was about \$60.02.⁴⁰

Some studies have found large variations in drug use patterns among states. The reasons for such variation may reflect differences in composition of Medicaid enrollment, drug policies in effect in the state, and/or different physician prescribing behaviors.⁴¹

³⁹ (...continued)

Medicaid HMOs enroll many more children and adults than aged or disabled individuals, the exclusion of managed care drug payments might have a greater relative impact on estimates of average spending among children and adults.

⁴⁰ Pharmaceutical Benefits Under State Medical Assistance Programs 2004.

⁴¹ B. Stuart, B.A. Briesacher, F. Ahern, D. Kidder, C. Zacker, G. Erwin, D. Gilden, and C. Fahlman "Drug Use and Prescribing Problems in Four State Medicaid Programs," *Health Care Financing Review*, vol. 20, no. 3, spring 1999.

Spending on Top Five Therapeutic Categories. The National Pharmaceutical Council (NPC) reported that, in 2003, almost 75% of Medicaid drug spending was for drugs in five categories: central nervous system drugs;⁴² cardiovascular drugs; anti-infective agents; gastrointestinal drugs; and hormones and synthetic substitutes. While state-by-state variation is large, spending on central nervous system drugs is by far the largest category for which Medicaid drug spending occurs. On average, spending for this class of drugs comprises about 37% of states' total drug spending.

Current Issues

Impact of MMA 2003

State Medicaid programs are undergoing major changes in response to the implementation of the provisions of the Medicare Prescription Drug, Improvements and Modernization Act of 2003 (MMA 2003, P.L. 108-173) signed in December of 2003. The new law provides that, as of the start of 2006, Medicaid eligibles who are also eligible for Medicare receive outpatient prescription drug coverage through the new Medicare prescription drug benefit instead of through Medicaid. While this law doesn't affect eligibility for Medicaid programs, it does, however, affect the benefits that Medicaid programs will cover. Under MMA 2003, state Medicaid programs will be prohibited from covering any drugs that are to be provided through the Medicare benefit, and cannot pay cost sharing amounts for those drugs.

States have both new administrative and financial obligations under MMA 2003. States are required to conduct eligibility determinations for the low-income subsidies and cost sharing assistance for the Medicare program. This is because the assistance for low-income Medicare Part D beneficiaries is based on the statutory description for a Medicaid coverage group — Qualified Medicare Beneficiaries (QMBs). QMBs are a group of dual eligible enrollees for whom Medicaid pays Medicare's cost sharing requirements. The group of individuals who qualify for low-income subsidies under Medicare Part D is similar to the QMB eligibility group, except that this group allows for somewhat higher income financial standards.

In addition, states will share in the cost of the new Medicare program based on a formula that projects what they would have paid for pharmacy benefits for the dual eligible population had the Medicare benefit not passed. Beginning in 2006, each state is required to make a monthly payment to the Secretary of HHS equal to the product of the state's share of 2003 Medicaid per capita spending for drugs for all full-benefit dual eligibles⁴³ trended forward to the current year, multiplied by the total number of such dual eligibles for such state for the month, and multiplied again by the "factor" for the month. The "factor" is 90% in 2006, and will phase down to 75%

⁴² A large classification of drugs that includes psychotherapeutics, treatments for seizure disorders and Parkinson's, and drugs for pain, among others.

⁴³ Including the estimated actuarial value of prescription drug benefits provided under a capitated care.

over 10 years. The formula ensures that states continue to fund a significant share of the cost of the new Medicare drug benefit for those individuals who would have otherwise been eligible for Medicaid prescription drugs. A state's failure to make the required payments will result in interest charges and in an offset to amounts otherwise payable under Medicaid.

An indirect impact of MMA 2003 on Medicaid programs will be that the rebate programs and collections will shrink considerably, since a large portion of Medicaid's prescription drugs will shift to being offered and covered through the Medicare program. For further information on the impact of Medicare Part D on Medicaid beneficiaries, see the following CRS reports: RL33268, *Medicare Prescription Drug Benefit: An Overview of Implementation for Dual Eligibles*, by Jennifer O'Sullivan and Karen Tritz, and CRS Report RS21837, *Implications of the Medicare Prescription Drug Benefit for Dual Eligibles and State Medicaid Programs*, by Karen Tritz.

Pharmacy Plus

Federal law gives states the flexibility to conduct demonstration projects as long as those projects promote the objectives of the Medicaid program. Under these demonstrations, states can waive many statutory eligibility and/or benefits rules. The current Administration has encouraged states to pursue targeted policies under a number of "waiver initiatives." One of those initiatives, called *Pharmacy Plus* waivers, encourages states to provide only pharmacy benefits to low-income seniors and individuals with disabilities who do not otherwise qualify for Medicaid drug coverage. To date, these demonstrations have provided comprehensive pharmacy benefits for low-income seniors and individuals with disabilities with income at or below 200% FPL. According to CMS's website, at the start of this year, there were three states that were using a Pharmacy Plus waivers to obtain federal matching funds for prescription drug benefit programs.⁴⁴ These program are expected to undergo significant changes as the Medicare prescription drug benefit takes over the provision of prescription drug for many of the individuals served by the programs.

⁴⁴ See the following CMS websites: [<http://www.cms.hhs.gov/MedicaidPharmacyPlus/>] and [<http://www.cms.hhs.gov/MedicaidStWaivProgDemoPGI/MWDL/list.asp#TopOfPage>].

Glossary

Actual Acquisition Cost (AAC) — Pharmacist’s or provider’s payments made to purchase a drug from any source (e.g., manufacturer, wholesaler) net of discounts, rebates, etc.

Average wholesale price (AWP) — Intended to reflect the average price at which pharmaceutical products are purchased from wholesalers. In reality, it is more like a manufacturer’s suggested wholesale price to the retailer, listed in any of the published compendia of cost. In 2003 the compendia include the *American Druggist First DataBank Annual Directory of Pharmaceuticals (Blue Book)*, and *Medi-Span’s Pricing Guide*, and Medical Economic’s *Drug Topics Redbook*.

Average manufacturers price (AMP) — the average price paid to a manufacturer by wholesalers for a drug. AMP was created as a benchmark for the purpose of calculating Medicaid rebates (OBRA 1990) and is not publically available.

Average Sales Price (ASP) — A new system created by federal and state prosecutors in settlements with pharmaceutical manufacturers TAP and Bayer to ensure more accurate price reporting and more recently applied to Medicare products paid under Part B of the program. ASP is the weighted average of all non-federal sales to wholesalers and is net of chargebacks, discounts, rebates, and other benefits tied to the purchase of the drug product, whether it is paid to the wholesaler or the retailer.

“Best price” — with respect to single source and innovator multiple source drugs, the lowest price at which the manufacturer sells the covered outpatient drug to any purchaser (excluding depot prices and single award contract prices of any federal agency, prices charged by manufacturers to DVA, DOD, PHS and various PHS-funded health programs, and state (non-Medicaid) pharmaceutical assistance programs) in the United States. Used to calculate rebates due for those drugs.

Dispensing fee — a payment to cover the cost of the pharmacist’s professional services in filling and dispensing a prescription.

Estimated acquisition cost (EAC) — the Medicaid agency’s best estimate of the price paid by pharmacists or providers.

Formulary — a list of drug products that may be dispensed or reimbursed. Insurers or states may create a “closed” (or “restricted”) formulary where only those drug products listed will be reimbursed by that plan or program. Other formularies may have no restrictions (“open” formularies) or may have certain restrictions such as higher patient cost sharing requirements for off-formulary drugs.

Maximum allowable cost (MAC) — A maximum dollar amount the pharmacist is paid for selected products.

Multiple source drug — a drug that is made available by at least three different suppliers, and the FDA has determined that at least three approved formulations of the drug are “therapeutically equivalent” that is, contain identical doses of the active

ingredient and have the same biological effects. *Innovator multiple source drugs* are those that are marketed under an original new drug application (NDA) approved by the FDA. *Non-innovator multiple source drugs* are all other multiple source drugs.

Original new drug application — an FDA-approved drug or biological application that received one or more forms of patent protection, patent extension or marketing exclusivity rights granted by the FDA.

Pharmaceutical benefit managers (PBMs) — Entities that contract with health insurers to manage pharmaceutical benefits. Activities provided by PBMs could include claims payment; administrative services, such as retail pharmacy network development; mail order pharmacy operation; formulary development; manufacturer rebate negotiation and prescription checks for adverse drug interactions; and negotiating discounts on pharmaceuticals products.

Single source drug — A covered outpatient drug that is produced or distributed under an original NDA approved by the FDA, including a drug product marketed by any cross-licensed producers or distributors operating under the NDA.

Stop-loss — A specified annual threshold for medical services to be paid by an insured person. Once the threshold is reached, the insurance coverage commences.

Wholesale acquisition cost (WAC) — The wholesaler's net payment made to purchase a drug product from the manufacturer, net of purchasing allowances and discounts.

Sources: E.K. Adams, Emory University School of Public Health, Atlanta, GA and K. Gondek, HCFA as published in the *Health Care Financing Review*, vol. 15, no. 3, spring 1994, p. 26; State Medicaid Manual, Part Six, Transmittal 36, Apr. 2000; Federal Regulations.